Travoprost
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Travoprost: From Open-Angle Glaucoma to Visceral Calciphylaxis
One-Sentence Summary
Travoprost is a topical prostaglandin F2-alpha analog, originally used to lower eye pressure in open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may be effective for visceral calciphylaxis, but there are 0 clinical trials and 0 publications directly supporting this prediction. This is a model-only prediction with no real-world evidence behind it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Open-angle glaucoma, ocular hypertension |
| Predicted New Indication | Visceral calciphylaxis |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, travoprost is an FP receptor agonist (a prostaglandin F2-alpha analog). It lowers eye pressure by increasing uveoscleral outflow of fluid from the eye.
The link between glaucoma and visceral calciphylaxis (a vascular calcification condition affecting internal organs) is weak. Travoprost is applied to the eye in tiny doses with minimal systemic exposure. No plausible mechanism connecting it to vascular calcification in visceral tissue has been established. The very high score (close to 100%) reflects the model's graph-based pattern matching, not biological or clinical support.
Other top-ranked predictions show the same pattern. They include thoracic outlet syndromes (venous, arterial, neurogenic), vascular disease, angiodysplasia of the stomach, blue toe syndrome, spontaneous coronary artery dissection, lymphangiectasis and hemangioendothelioma. All of them lack trials or literature, and none has a clear mechanistic link to topical travoprost.
Clinical Trial Evidence
Currently no clinical trials are registered for visceral calciphylaxis.
For reference, the broader "vascular disease" prediction (rank 5) retrieved the trials below. They are all in glaucoma or ocular hypertension, and none tests travoprost in vascular disease:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00308945 | Phase 4 | Completed | 20 | Travoprost vs latanoprost effects on retinal vascular diameter and choroidal blood flow in glaucoma; a physiological outcome, not a vascular disease trial |
| NCT02136589 | Phase 4 | Completed | 40 | NSAID pretreatment and travoprost-induced conjunctival hyperemia (a side effect) |
| NCT00293800 | Phase 3 | Completed | 173 | Glaucoma therapy in open-angle glaucoma or ocular hypertension |
| NCT00293761 | Phase 3 | Completed | 109 | Glaucoma therapy in open-angle glaucoma or ocular hypertension |
| NCT00293787 | Phase 3 | Completed | 156 | Glaucoma therapy in open-angle glaucoma or ocular hypertension |
| NCT00672997 | Phase 3 | Completed | 301 | Travoprost/timolol BAC-free vs standard combination in glaucoma |
| NCT00760539 | Phase 3 | Completed | 87 | Travoprost/timolol BAC-free vs standard combination in glaucoma (Japan) |
| NCT02140060 | Phase 2 | Completed | 327 | Travoprost/brinzolamide fixed combination for IOP lowering |
| NCT01510145 | Phase 4 | Completed | 191 | BAK-free travoprost after latanoprost monotherapy in glaucoma |
| NCT00047554 | N/A | Terminated | 336 | Five-year safety study of iris pigmentation changes with Travatan |
Literature Evidence
Currently no related literature is available for visceral calciphylaxis.
For reference, the literature below was retrieved for the related "vascular disease" and "hemangioendothelioma" predictions. It concerns glaucoma and ocular side effects, not a therapeutic benefit in the predicted conditions:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22167538 | 2012 | Meta-analysis | Eur J Ophthalmol | IOP-lowering and tolerability of prostaglandin-timolol fixed combinations |
| 23231442 | 2013 | Meta-analysis | J Ocul Pharmacol Ther | Prostaglandin analogs with timolol, fixed vs unfixed combinations, in open-angle glaucoma |
| 25867658 | 2015 | Systematic Review | Curr Med Res Opin | Updated review of efficacy and tolerability of prostaglandin-timolol combinations |
| 19019922 | 2009 | Systematic Review | Br J Ophthalmol | Conjunctival hyperaemia with latanoprost vs travoprost and bimatoprost |
| 31335731 | 2019 | Review | Medicine | Protocol for evaluating travoprost efficacy in glaucoma |
| 12648301 | 2003 | Review | J Ocul Pharmacol Ther | Hyperemia occurs in up to 50% of patients on travoprost |
| 19107053 | 2008 | Case report | J Fr Ophtalmol | Uveal effusion with retinal detachment induced by topical travoprost in a patient with Sturge-Weber-Krabbe syndrome |
| 26847553 | 2016 | Observational study | Jpn J Ophthalmol | Quantitative link between glaucoma eye drops and conjunctival hyperemia |
| 24070367 | 2013 | Randomized study | J Ocul Pharmacol Ther | Bimatoprost 0.01% vs travoprost/timolol after latanoprost and timolol |
| 26563363 | 2015 | Open-label study | BMC Ophthalmol | BAK-free travoprost on IOP and ocular surface symptoms after latanoprost |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15446P | TRAVON EYE DROPS SOLUTION 0.004% | Sterile solution | Not specified in the data |
| SIN15206P | TRAVATAN C EYE DROP SOLUTION 30MCG/ML | Sterile solution | Not specified in the data |
| SIN13722P | DuoTrav Eye Drops, Solution (5mg/40mcg) per mL | Sterile solution | Not specified in the data |
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): uveitis, iris disease, ciliary body disease, panuveitis, iritis, cystoid macular edema, macular retinal edema.
- Related safety signals in the literature: conjunctival hyperemia (up to about 50% of patients in one review), iris pigmentation changes, and a case report of uveal effusion with exudative retinal detachment in a patient with Sturge-Weber-Krabbe syndrome, suggesting caution in patients with abnormal choroidal vasculature.
- Drug Interactions: 49 interactions were identified, but severity is unclassified (level "Unknown"). Listed examples include calcitriol, pantoprazole, sucralfate, morphine, metformin, omeprazole, prednisone, prednisolone, triamcinolone, simvastatin and acetylsalicylic acid. These need pharmacist review before any conclusion is drawn.
For package insert warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score (Evidence Level L5). There are no trials or publications for visceral calciphylaxis, and there is no plausible mechanism for a topical eye drop with minimal systemic exposure. Retrieved evidence for related vascular terms is entirely about glaucoma and appears to be a keyword-matching artifact. The same applies to all other top-ranked predictions.
To proceed, the following is needed:
- Detailed mechanism of action data and a biological rationale linking FP receptor agonism to vascular calcification
- Preclinical evidence (cell or animal models) of an effect on calcification
- Evidence that a non-ocular route or formulation could achieve relevant systemic exposure (route compatibility is currently unassessed)
- Package insert warnings and contraindications from the HSA, with severity classification of drug interactions
- A review of whether any other predicted indication has a more credible mechanistic basis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.